Scholarlink

Background <p>Colchicine has gained attention for its potential cardiovascular benefits, particularly in patients at high cardiovascular risk. This study aims to assess the impact of colchicine on these primary outcomes in adults with high cardiovascular risk.</p> Methods <p>Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, EMBASE, Cochrane Library, and Web of Science) to identify eligible studies reported up to December 16, 2024. Using Review Manager software, we reported outcomes as risk ratios (RRs) and confidence intervals (CIs). A p-value &lt; 0.05 is considered statistically significant. The study was registered on PROSPERO (CRD42024589252).</p> Results <p>The meta-analysis included a total of 12 studies with 24,412 patients. Overall, the results showed insignificant differences in all-cause mortality 1.04 (RR 1.04, 95% CI: 0.88–1.24, <i>p</i> = 0.63), or cardiovascular mortality (RR 0.82, 95% CI: 0.61–1.11, <i>p</i> = 0.20) between colchicine and placebo. However, compared to placebo, colchicine significantly reduced the risk of myocardial infarction (RR = 0.75, 95% CI: 0.60–0.92, <i>p</i> &lt; 0.01), major adverse cardiac and cerebrovascular events (RR = 0.77, 95% CI: 0.68–0.87, <i>p</i> &lt; 0.01), revascularization (RR = 0.61, 95% CI: 0.42–0.89, <i>p</i> = 0.01) and incidence of ischemic stroke – only in patients with acute coronary syndrome (RR 0.35, 95% CI: 0.16–0.74, <i>p</i> &lt; 0.01).</p> Conclusion <p>Incorporating colchicine into standard secondary prevention regimens for patients with coronary artery disease or acute coronary syndrome has been shown to reduce the incidence of cardiovascular and cerebrovascular events effectively.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Colchicine for Secondary Prevention in Cardiovascular Diseases: A Systematic Review and Meta-Analysis of RCTs

  • 期刊论文

  • 发表日期：

    2026年2月7日

查看全文
  • Mohammad Tanashat,
  • Basma Badrawy Khalefa,
  • Abdelrahman Eletrreby,
  • Mohamed Abuelazm,
  • Mohamed Abouzid,
  • Mohammed Ayyad,
  • Moumen Arnaout,
  • Obieda Altobaishat,
  • Omar Abdullah Bataineh,
  • Mohamed Hariri,
  • Almothana Manasrah,
  • Zaid Bataineh,
  • Ramy Galy

摘要

Background

Colchicine has gained attention for its potential cardiovascular benefits, particularly in patients at high cardiovascular risk. This study aims to assess the impact of colchicine on these primary outcomes in adults with high cardiovascular risk.

Methods

Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, EMBASE, Cochrane Library, and Web of Science) to identify eligible studies reported up to December 16, 2024. Using Review Manager software, we reported outcomes as risk ratios (RRs) and confidence intervals (CIs). A p-value < 0.05 is considered statistically significant. The study was registered on PROSPERO (CRD42024589252).

Results

The meta-analysis included a total of 12 studies with 24,412 patients. Overall, the results showed insignificant differences in all-cause mortality 1.04 (RR 1.04, 95% CI: 0.88–1.24, p = 0.63), or cardiovascular mortality (RR 0.82, 95% CI: 0.61–1.11, p = 0.20) between colchicine and placebo. However, compared to placebo, colchicine significantly reduced the risk of myocardial infarction (RR = 0.75, 95% CI: 0.60–0.92, p < 0.01), major adverse cardiac and cerebrovascular events (RR = 0.77, 95% CI: 0.68–0.87, p < 0.01), revascularization (RR = 0.61, 95% CI: 0.42–0.89, p = 0.01) and incidence of ischemic stroke – only in patients with acute coronary syndrome (RR 0.35, 95% CI: 0.16–0.74, p < 0.01).

Conclusion

Incorporating colchicine into standard secondary prevention regimens for patients with coronary artery disease or acute coronary syndrome has been shown to reduce the incidence of cardiovascular and cerebrovascular events effectively.